Public Employees Retirement Association of Colorado increased its stake in Chemours Company (The) (NYSE:CC) by 17.2% during the second quarter, Holdings Channel reports. The firm owned 39,521 shares of the specialty chemicals company’s stock after buying an additional 5,812 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Chemours Company (The) were worth $1,499,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in CC. Nationwide Fund Advisors raised its position in Chemours Company (The) by 262.6% in the first quarter. Nationwide Fund Advisors now owns 413,027 shares of the specialty chemicals company’s stock valued at $15,902,000 after buying an additional 299,121 shares during the period. Ameritas Investment Partners Inc. raised its position in Chemours Company (The) by 349.0% in the first quarter. Ameritas Investment Partners Inc. now owns 69,460 shares of the specialty chemicals company’s stock valued at $2,674,000 after buying an additional 53,991 shares during the period. Pacer Advisors Inc. bought a new position in Chemours Company (The) during the first quarter valued at approximately $917,000. Dynamic Technology Lab Private Ltd raised its position in Chemours Company (The) by 60.5% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,325 shares of the specialty chemicals company’s stock valued at $974,000 after buying an additional 9,549 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Chemours Company (The) by 51.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 491,439 shares of the specialty chemicals company’s stock valued at $10,856,000 after buying an additional 167,183 shares during the period. 75.21% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Chemours Company (NYSE:CC) opened at 46.34 on Friday. The stock has a market capitalization of $8.56 billion, a P/E ratio of 30.33 and a beta of 3.63. Chemours Company has a 12-month low of $11.33 and a 12-month high of $51.51. The firm’s 50-day moving average price is $43.52 and its 200 day moving average price is $38.05.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the company earned $0.27 EPS. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts predict that Chemours Company will post $3.51 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be paid a dividend of $0.03 per share. The ex-dividend date is Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.26%. Chemours Company (The)’s payout ratio is 8.11%.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/public-employees-retirement-association-of-colorado-buys-5812-shares-of-chemours-company-the-cc/1480424.html.

CC has been the topic of several recent research reports. Citigroup Inc. boosted their price target on Chemours Company (The) from $62.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, April 17th. ValuEngine raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co raised Chemours Company (The) from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $39.00 to $50.00 in a research report on Friday, May 12th. Zacks Investment Research raised Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research report on Friday, July 14th. Finally, BidaskClub lowered Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Chemours Company (The) presently has an average rating of “Buy” and an average price target of $51.50.

In related news, VP Erich Parker sold 4,908 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul Kirsch sold 19,036 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.